tert-butyl 4-(2-(5-(3-methoxyphenylthio)-4-(2-methylpyridin-3-yloxy)pyridin-2-ylamino)thiazol-4-yl)piperidine-1-carboxylate | 1043022-93-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl 4-(2-(5-(3-methoxyphenylthio)-4-(2-methylpyridin-3-yloxy)pyridin-2-ylamino)thiazol-4-yl)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-(2-(5-(3-methoxyphenylthio)-4-(2-methylpyridin-3-yloxy)pyridin-2-ylamino)thiazol-4-yl)piperidine-1-carboxylate；tert-butyl 4-[2-[[5-(3-methoxyphenyl)sulfanyl-4-(2-methylpyridin-3-yl)oxypyridin-2-yl]amino]-1,3-thiazol-4-yl]piperidine-1-carboxylate
• CAS: 1043022-93-0
• 化学式: C₃₁H₃₅N₅O₄S₂
• 分子量: 605.782
• InChiKey: UXCWUOUZUBHHTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  42
• 可旋转键数：
  10
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  152
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  tert-butyl 4-(2-(5-bromo-4-(2-methylpyridin-3-yloxy)pyridin-2-ylamino)thiazol-4-yl)piperidine-1-carboxylate 、 3-甲氧基苯硫酚 在 tris-(dibenzylideneacetone)dipalladium(0) 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 potassium phosphate 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以51%的产率得到tert-butyl 4-(2-(5-(3-methoxyphenylthio)-4-(2-methylpyridin-3-yloxy)pyridin-2-ylamino)thiazol-4-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  WO2008/91770

  摘要：

  公开号：

文献信息

• 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS
  申请人：Aicher Thomas Daniel

  公开号：US20100099713A1

  公开（公告）日：2010-04-22

  Provided are compounds having the Formula I or salts thereof, wherein R 2 , L, R 3 , R 11 , D 2 and R 13 are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供的化合物具有I式或其盐，其中R2、L、R3、R11、D2和R13的定义如本文所述，可用于治疗和/或预防由葡萄糖激酶活性不足引起的疾病，如糖尿病。还提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶治疗的疾病和疾病的方法。
• 2-aminopyridine derivatives as glucokinase activators
  申请人：Aicher Thomas Daniel

  公开号：US08431713B2

  公开（公告）日：2013-04-30

  Provided are compounds having the Formula I or salts thereof, wherein R2, L, R3, R11, D2 and R13 are as defined herein, that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.

  提供了具有公式I或其盐的化合物，其中R2、L、R3、R11、D2和R13的定义如本文所述，这些化合物在治疗和/或预防由葡萄糖激酶活性不足介导的疾病，如糖尿病等方面是有用的。还提供了治疗或预防由葡萄糖激酶活性不足或可以通过激活葡萄糖激酶治疗的疾病和疾病的方法。
• US8431713B2
  申请人：——

  公开号：US8431713B2

  公开（公告）日：2013-04-30
• [EN] 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS<br/>[FR] DÉRIVÉS DE 2-AMINOPYRIDINE UTILISÉS COMME ACTIVATEURS DE LA GLUCOKINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2008091770A1

  公开（公告）日：2008-07-31

  [EN] Provided are compounds having the Formula (I) or salts thereof, wherein: L is O, S, SO, SO₂, CHOH, C(O), or CH₂; D² is CR¹² or N; R² is aryl, heteroaryl, saturated or partially unsaturated cycloalkyl, or saturated or partially unsaturated heterocyclyl (optionally substituted with oxo), wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl are monocyclic or bicyclic and are further optionally substituted with one or more groups independently selected from C₁-C₆ alkyl, F, Cl, Br, I, CF₃, CN, OR⁶, C(=O)R⁶, C(=O)OR⁶, O(CH₂)_nC(=O)OR⁶, C(=O)NR⁶R⁷, NO₂ and (1-6C alkyl)OR⁶; R³ is H, Br, OR⁶, SR⁶, C(O)OR⁶, C(O)NR⁶R⁷, C(O)R⁶, heteroaryl, or C₁-C₆ alkyl substituted with one or more groups independently selected from V_n-aryl, V_n-OR⁶, V_n- C(=O)OR⁶ and V_n-NR⁶R⁷; R¹¹ is H or Cl; and R¹³ is N-(1 -6C alkanoyl)piperidin-4-yl; that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.
  [FR] L'invention concerne des composés de formule (I) ou des sels de ceux-ci, L représentant O, S, SO, SO₂, CHOH, C(O) ou CH₂; D² représentant CR¹² ou N; R² représentant aryle, hétéroaryle, cycloalkyle saturé ou partiellement insaturé ou hétérocyclyle saturé ou partiellement insaturé (éventuellement substitué par oxo), lesdits aryle, hétéroaryle, cycloalkyle et hétérocyclyle étant monocycliques ou bicycliques et étant par ailleurs éventuellement substitués par un ou plusieurs groupes choisis indépendamment parmi alkyle C₁-C₆, F, Cl, Br, I, CF₃, CN, OR⁶, C(=O)R⁶, C(=O)OR⁶, O(CH₂)_nC(=O)OR⁶, C(=O)NR⁶R⁷, NO₂ et (1-6C alkyl)OR⁶; R³ représentant H, Br, OR⁶, SR⁶, C(O)OR⁶, C(O)NR⁶R⁷, C(O)R⁶, hétéroaryle ou alkyle C₁-C₆ substitué par un ou plusieurs groupes choisis indépendamment parmi V_n-aryle, V_n-OR⁶, V_n-C(=O)OR⁶ et V_n-NR⁶R⁷; R¹¹ représentant H ou Cl; et R¹³ représentant N-(1-6C alcanoyl)pipéridin-4-yle; ces composés étant utiles dans le traitement et/ou la prévention de maladies à médiation par des niveaux déficients de l'activité glucokinase, telles que le diabète sucré. L'invention concerne également des procédés de traitement ou de prévention de maladies ou de troubles caractérisés par une activité déficiente de la glucokinase ou qui peuvent être traités par activation de la glucokinase.
• WO2008/91770
  申请人：——

  公开号：——

  公开（公告）日：——